Studies on an Inhibitor of Plasminogen Activation in Human Serum

Summary

A procedure is described for partial purification of an inhibitor of the activation of plasminogen by urokinase and streptokinase. The method involves specific adsorption of contammants, ion-exchange chromatography on DEAE-Sephadex, gel filtration on Sephadex G-200 and preparative electrophoresis. The inhibitor fraction contained no antiplasmin, no plasminogen, no α₁-antitrypsin, no antithrombin-III and was shown not to be α₂ M or inter-α-inhibitor. It contained traces of prothrombin and cerulo-plasmin. An antiserum against the inhibitor fraction capable of neutralising the inhibitor in serum was raised in rabbits.

• References

• 1 Aoki N, and v. Kaulla K. N. 1971; Human serum plasminogen antiaotivator : its distinction from antiplasmin. American Journal of pathology 220: 1137.
• 2 Axén R, Porhath J, and Eenback S. 1967; Chemical coupling of peptides and proteins to polysaccharides by means of cyanogen halides. Nature 214: 1302.
• 3 Bennett N. B. 1967; A method for the quantitative assay of inhibitor of plasminogen activation in human serum. Thrombosis et Diathesis Haemorrhagica 17: 12.
• 4 Bennett N. B. 1970; Further studies on an inhibitor of plasminogen activation in human serum. Thrombosis et Diathesis Haemorrhagica 23: 553.
• 5 Blomback B, and Blomback M. 1956; Purification of human and bovine fibrinogen. Arkiv for Kemi 10: 415.
• 6 Brakman P, Mohler E. R, and Astrup T. 1966; A group of patients with impaired plasma fibrinolytic system and selective inhibition of tissue activator-induced fibrinolysis. Scandinavian Journal of Haematology 3: 389.
• 7 Davis B. J. 1964; Disc electrophoresis. II. Method and application to human serum proteins. Annals of the New York Academy of Sciences 121: 404.
• 8 Ekelund H, Hedner U, and Nilsson I. M. 1970; Fibrinolysis in newborns. Acta Paediatrioa Scandinavica 59: 33.
• 9 Eriksson S. 1965 Studies in α₁-antitrypsin deficiency. Acta Medica Scandinavica, Suppl. 432.
• 10 Ganrot P. O. 1966; Determination of α₂-macroglobulin as trypsin-protein esterase. Clinica Chimica Acta 14: 493.
• 11 Ganrot P. O. 1972; Crossed Immunoelectrophoresis. The Scandinavian Journal of Clinical & Laboratory Investigation 124: 39.
• 12 Ganrot P. O, and Niléhn J.-E. 1968; Immunochemical determination of human plasminogen. Clinica Chimica Acta 22: 335.
• 13 Hedner U, and Nilsson I. M. 1965; Determination of plasminogen in human plasma by a casein method. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 14: 545.
• 14 Hedner U, Nilsson I. M, and Jacobsen C. D. 1970; Demonstration of low content of fibrinolytic inhibitors in individuals with high fibrinolytic capacity. The Scandinavian Journal of Clinical and Laboratory Investigation 25: 329.
• 15 Heide K, Heimburger N, and Haupt H. 1965; An inter-alphatrypsin inhibitor of human serum. Clinica Chimica Acta 11: 82.
• 16 Jacobsen C. D. 1968; Proteolytic capacity in human plasma. Part I. Measurement of proteolytic activity in the presence of natural inhibitors and study of the interindividual variations. The Scandinavian Journal of Clinical and Laboratory Investigations 21: 216.
• 17 Kawano T, Morimoto K, and TJemura Y. 1970; Partial purification and properties of urokinase inhibitor from human placenta. The Journal of Biochemistry 67: 333.
• 18 Kröll J. 1968; On the immunoelectrophoretical identification and quantitation of serum proteins. The Scandinavian Journal of Clinical and Laboratory Investigation 22: 79.
• 19 Laurell C. B. 1966; Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Analytical Biochemistry 15: 45.
• 20 Lauritsen O. S. 1968; Urokinase inhibitor in human plasma. The Scandinavian Journal of Clinical and Laboratory Investigation 22: 314.
• 21 Lauritsen O. S. 1970 The fibrinolytic enzyme system and trypsin inhibitor as measured by the casein method. Danish Medical Bulletin, 17, Suppl. II.
• 22 McNicol G. P, Gale S. B, and Douglas A. S. 1963; In-vitro and in-vivo studies of a preparation of urokinase. British Medical Journal 1: 909.
• 23 Müllertz S. 1954 The plasmin activator system in human blood. Proceedings of the 1st international conference on thrombosis and embolism, Basel, P. 79.
• 24 Müllertz S. 1955; Formation and properties of the activator of plasminogen and human and bovine plasmin. Biochemical Journal 61: 424.
• 25 Nilehn J.-E, and Nilsson I. M. 1964; Demonstration of fibrinolytic split products in human serum by an immunological method in spontaneous and induced fibrinolytic states. Scandinavian Journal of Haematology 1: 313.
• 26 Nilsson I. M, Krook H, Sternby IST. H, Söderberg E, and Söderström N. 1961; Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta Medica Scandinavica 169: 323.
• 27 Owren P. A, and Aas K. 1951; The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. The Scandinavian Journal of Clinical and Laboratory Investigation 3: 201.
• 28 Pandolfi M, Hedner I.I, and Nilsson I. M. 1970; Bilateral occlusion of the retinal veins in a patient with inhibition of fibrinolysis. Annals of Ophthalmology 2: 481.
• 29 Paraskevas M, Nilsson I. M, and Martinsson G. 1962; A method for determining serum inhibitors of plasminogen activation. The Scandinavian Journal of Clinical and Laboratory Investigation 14: 138.
• 30 Shamash Y, and Rimon A. 1964; The plasmin inhibitors of plasma. I. A method for their estimation. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 12: 119.
• 31 Uszynski M, and Abildgaard U. 1971; Separation and characterization of two fibrinolytic inhibitors from human placenta. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 25: 580.
• 32 Whitaker J. R. 1963; Determination of molecular weights of proteins by gel filtration on Sephadex. Analytical Chemistry 35: 1950.